Roderick Verhelst
Inversor de Capital Privado en Bioqube Ventures NV .
Perfil
Roderick Verhelst is a principal at Bioqube Ventures with strong investment interest in early-stage therapeutics.
He obtained a PhD in Bioengineering at the University of Leuven and an MBA at the Solvay Brussels School of Economics & Management.
Prior to joining Bioqube Ventures, Roderick was a principal at Participatiemaatschappij Vlaanderen (PMV).
Here, he built a successful track record in life science investing and was instrumental in the formation, financing and/or exit of several start-ups, including GST (acquired by Boehringer Ingelheim), Bluebee (acquired by Illumina), Dualyx and Flamingo Therapeutics.
He served on the Board of Directors of these companies as well as Confo Therapeutics, miDiagnostics and Aelin Therapeutics.
Before his role at PMV, Roderick was an investment banker (equity research) at Degroof Petercam, where he was responsible for the life science franchise and was involved in the IPOs of argenx, Biocartis, Curetis, and Probiodrug (now Vivoryon), among others.
Cargos activos de Roderick Verhelst
Empresas | Cargo | Inicio |
---|---|---|
Bioqube Ventures NV | Inversor de Capital Privado | 01/01/2022 |
Antiguos cargos conocidos de Roderick Verhelst.
Empresas | Cargo | Fin |
---|---|---|
Participatiemaatschappij Vlaanderen NV
Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Inversor de Capital Privado | 01/01/2022 |
Dualyx NV
Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Director/Miembro de la Junta | 01/01/2022 |
miDIAGNOSTICS NV
miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services miDIAGNOSTICS NV develops a computer chip powered portable medical laboratory. The company is headquartered in Leuven, Belgium. | Director/Miembro de la Junta | 01/01/2022 |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Director/Miembro de la Junta | 01/05/2021 |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Director/Miembro de la Junta | 01/03/2021 |
Formación de Roderick Verhelst.
Katholieke Universiteit Leuven | Graduate Degree |
Solvay Business School of Economics & Management | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 9 |
---|---|
Petercam SA (Broker)
Petercam SA (Broker) Investment Banks/BrokersFinance Petercam SA (Broker) is the brokerage division of Petercam SA, a subsidiary of Banque Degroof SA (BSE: 698814) in Belgium. Eestablished in 1968 when family-owned brokerage houses Libert-Peterbroeck and Van Campenhout merged, the firm is headquartered in Brussels with a network of Belgian branches. | Finance |
Banque Degroof Petercam SA (Broker)
Banque Degroof Petercam SA (Broker) Investment Banks/BrokersFinance Banque Degroof Petercam SA (Broker) (Banque Degroof-Broker) is the broker/dealer division of Banque Degroof Petercam SA, a public company headquartered in Brussels, Belgium. Banque Degroof-Broker offers order execution in different asset classes for businesses, investors and institutional clients. | Finance |
Participatiemaatschappij Vlaanderen NV
Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Finance |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Commercial Services |
Bioqube Ventures NV | Finance |
Dualyx NV
Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Commercial Services |
miDIAGNOSTICS NV
miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services miDIAGNOSTICS NV develops a computer chip powered portable medical laboratory. The company is headquartered in Leuven, Belgium. | Commercial Services |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Health Technology |
Global Stem Cell Technology NV
Global Stem Cell Technology NV BiotechnologyHealth Technology Global Stem Cell Technology NV develops blood-derived mesenchymal stem cells for clinical use in horses. GST not only focusses on the preparation of stem cell samples, but also on the scientific research in order to improve currently available therapies. The company was founded by Jan H. Spaas in 2012 and is headquartered in Evergem, Belgium. | Health Technology |
- Bolsa de valores
- Insiders
- Roderick Verhelst